NYSE:JNJ 30 January 2026 - 15 February 2026

Johnson & Johnson stock hovered near $238.70 in late morning Tuesday, showing little movement as investors took in a newly posted conference schedule and fresh insider transaction filings. Shares have traded between $237.89 and $240.52 during the session.

Johnson & Johnson stock climbed 0.9% to finish Friday at $239.99, landing close to its intraday peak, after a New Jersey appeals court ejected a major plaintiffs’ firm from part of the company’s talc lawsuits. Roughly 8.3 million shares traded hands.

Johnson & Johnson shares ticked up on Friday, holding steady into after-hours. Investors weighed a New Jersey court’s latest move in the company’s ongoing talc litigation, along with a new FDA safety notice tied to select devices.

Johnson & Johnson shares inched higher on Friday, rising roughly 0.2% to $238.34 around midday, having peaked at $240.22 earlier. This kept the stock just above Thursday’s closing price of $237.79.

Johnson & Johnson shares jumped about 1.4% Thursday, then held steady after hours. The move came as the company asked the U.S. Supreme Court to weigh in on whether a shareholder lawsuit accusing it of misleading statements about talc safety can move forward as a class action. The petition seeks clarification on the court’s 2021 Goldman Sachs ruling, focusing on how “price impact” — whether alleged falsehoods affected stock prices — factors into certifying investor groups. JNJ last changed hands at $237.79, after trading between $233.33 and $240.00 during regular hours.

Johnson & Johnson shares climbed 1.3% to $237.59 in afternoon trading, pushing their recent gains further. The move came after the company petitioned the U.S. Supreme Court to review a shareholder lawsuit concerning claims about the safety of its talc products.

Johnson & Johnson shares climbed roughly 1% on Tuesday following an upgrade from RBC Capital Markets, which lifted its price target and kept focus on the company’s ongoing legal issues. The stock last traded at $233.10, fluctuating between $230.00 and $235.24, with about 9.3 million shares changing hands.

Johnson & Johnson shares edged down 3 cents to $227.25 on Friday after a U.S. judge dismissed a lawsuit accusing the company of fraud related to its talc bankruptcy approach. The plaintiffs claimed J&J employed a “Texas two-step,” moving talc liabilities into a subsidiary that filed for bankruptcy to stall cancer lawsuits. Judge Michael Shipp ruled they hadn’t proven any real harm caused by the delay. J&J’s litigation head Erik Haas slammed the claims as “wholly meritless,” while the plaintiffs’ attorney said they’re considering an appeal.

Johnson & Johnson shares closed nearly flat Friday following Michael Shipp’s dismissal of a fraud lawsuit tied to the company’s failed talc-bankruptcy plan. The stock ended at $227.25, slipping just 0.01% after fluctuating between $225.34 and $228.40 throughout the session. Erik Haas labeled the allegations “wholly meritless,” while plaintiffs’ attorney Patricia Kipnis said she’s reviewing the ruling with clients to consider an appeal.

Johnson & Johnson shares held steady in midday trading Friday after a U.S. judge threw out a lawsuit alleging the company committed fraud to route talc claims through bankruptcy. The company also announced that a European drug panel supported a wider label for its AKEEGA prostate cancer treatment.